Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CVKD 
Cadrenal Therapeutics, Inc. Common Stock (CVKD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: CVKD (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $35.67
1 Year Target Price $35.67
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.4% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 26.53M USD | Price to earnings Ratio - | 1Y Target Price 35.67 |
Price to earnings Ratio - | 1Y Target Price 35.67 | ||
Volume (30-day avg) 2 | Beta 0.95 | 52 Weeks Range 6.89 - 22.90 | Updated Date 08/30/2025 |
52 Weeks Range 6.89 - 22.90 | Updated Date 08/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.88 |
Earnings Date
Report Date 2025-08-11 | When - | Estimate -1.26 | Actual -1.87 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -157.41% | Return on Equity (TTM) -340.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 22165559 | Price to Sales(TTM) - |
Enterprise Value 22165559 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.21 | Shares Outstanding 2046850 | Shares Floating 1469907 |
Shares Outstanding 2046850 | Shares Floating 1469907 | ||
Percent Insiders 28.19 | Percent Institutions 7.23 |
Upturn AI SWOT
Cadrenal Therapeutics, Inc. Common Stock
Company Overview
History and Background
Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular and endocrine diseases. Founded in 2016, it has focused on progressing its lead product candidate, tecarfarin, through clinical development.
Core Business Areas
- Pharmaceutical Development: Focuses on developing and commercializing tecarfarin, a novel Vitamin K antagonist, for thromboembolic disorders and antithrombotic therapy.
Leadership and Structure
As of current information, the leadership team consists of experienced executives in the pharmaceutical industry. The company's structure typically includes departments for research and development, clinical operations, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- Tecarfarin: A novel Vitamin K antagonist in development for thromboembolic disorders and antithrombotic therapy. As it's still in clinical trials, there is no current market share or revenue. Competitors include warfarin and direct oral anticoagulants (DOACs) from companies like Bristol-Myers Squibb (BMY) and Johnson & Johnson (JNJ).
Market Dynamics
Industry Overview
The pharmaceutical industry for cardiovascular and endocrine diseases is large and competitive, with significant unmet needs in specific patient populations. The anticoagulation market is mature but innovation in safety and efficacy is constantly sought after.
Positioning
Cadrenal Therapeutics is positioned as a company developing a next-generation anticoagulant with potentially improved safety and efficacy compared to existing therapies. Their competitive advantage lies in the unique pharmacokinetic profile of Tecarfarin.
Total Addressable Market (TAM)
The total addressable market for anticoagulants is estimated to be in the billions of dollars globally. Cadrenal Therapeutics is targeting a specific niche within this market, focusing on patients who may benefit from tecarfarin's unique properties. The exact TAM they address will depend on the specific indications tecarfarin is approved for.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (Tecarfarin)
- Potential for improved safety profile compared to warfarin
- Experienced management team
Weaknesses
- Single product focus
- Early-stage clinical development
- Dependence on successful clinical trials and regulatory approvals
- Limited financial resources
Opportunities
- Successful completion of clinical trials leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion into new indications for Tecarfarin
- Growing demand for safer and more effective anticoagulants
Threats
- Failure of clinical trials
- Regulatory hurdles
- Competition from existing anticoagulants and new entrants
- Patent challenges
- Funding risks
Competitors and Market Share
Key Competitors
- Bristol-Myers Squibb (BMY)
- Johnson & Johnson (JNJ)
- Pfizer (PFE)
- Bayer (BAYRY)
Competitive Landscape
Cadrenal Therapeutics faces significant competition from established pharmaceutical companies with approved anticoagulants. Its success hinges on demonstrating superior safety or efficacy of Tecarfarin.
Growth Trajectory and Initiatives
Historical Growth: The company's growth has been focused on advancing Tecarfarin through clinical trials.
Future Projections: Future growth is dependent on the successful development and commercialization of Tecarfarin. Analyst estimates are speculative at this stage.
Recent Initiatives: Recent initiatives likely include the initiation or continuation of clinical trials for Tecarfarin and exploration of potential partnerships.
Summary
Cadrenal Therapeutics is a high-risk, high-reward biopharmaceutical company focused on developing Tecarfarin. Its success is contingent on the outcome of clinical trials. It faces strong competition in the established anticoagulant market. The company needs to ensure adequate funding to support its clinical development programs.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cadrenal Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Ponte Vedra, FL, United States | ||
IPO Launch date 2023-01-20 | Chairman & CEO Mr. Quang X. Pham | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.cadrenal.com |
Full time employees 4 | Website https://www.cadrenal.com | ||
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.